(Q37816261)

23 August 2017

1 reference

title

Denosumab: What's new? (English)

1 reference

23 August 2017

Cesar E Bogado

1

1 reference

23 August 2017

Maria Belen Zanchetta

2

1 reference

23 August 2017

Juan A Boailchuk

3

1 reference

23 August 2017

Fabio E Massari

4

1 reference

23 August 2017

Jose R Zanchetta

5

1 reference

23 August 2017

publication date

1 March 2011

1 reference

Current osteoporosis reports

23 August 2017

published in

1 reference

23 August 2017

volume

9

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

12-19

1 reference

Model structure and control of bone remodeling: a theoretical study.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-010-0040-1

A single-dose study of denosumab in patients with various degrees of renal impairment

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21132405

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Remodeling and skeletal fragility

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21132405

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21132405

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11914-010-0040-1

1 reference

23 August 2017

1 reference